Abstract 4085
Background
Lung cancer is the main cause of cancer death worldwide. Even in early stages the cancer-specific survival is poor due to disease relapse. The TNM classification is the strongest prognostic tool. The 8th AJCC edition has changed the cutpoints for stage, leading to a “stage shift” or a “stage decrease”, mainly reflecting changes in the prognostic score attributed to the tumor diameter. We have reviewed a cohort of patients that were treated before the benefit of adjuvant chemotherapy was proved, in order to corroborate which of the two classifications represents better the risk of recurrence.
Methods
Retrospective analysis of a cohort of 182 patients with lung cancer treated with complete resection and no adyuvant chemotherapy, between 1999 and 2006. Evaluation criteria: overall survival.
Results
1. Patient characteristics: median diagnostic age 68 years (39-86), 90% males, 48% current and 42% former smokers, 37% diagnosed of COPD. 2. Tumor characteristics:
- Histology: squamous 57%, adenocarcinoma 36%.
- Grade: 47% moderately differentiated, 33% undifferentiated. - Pathological staging by TNM edition.Table: 1351P
| 7th edition n (%) | 8th edition n (%) | ||
|---|---|---|---|
| IA | 44 (24) | IA1 | 5 (2.7) |
| IA2 | 23 (12.6) | ||
| IA3 | 26 (14.3) | ||
| IB | 69 (38) | IB | 30 (16) |
| IIA | 20 (11) | IIA | 27 (15) |
| IIB | 49 (26) | IIB | 46 (25) |
| IIIA | 0 | IIIA | 25 (14) |
3. median OS in our cohort of patients = 79 months (IC95% = 58-100) log Rank test p=NS me OS by pathological stage defined by 8th ed. AJCC: IA1 97 m (IC95% 37-158) IA2 108 m (IC95% 54-162) IA3 139 m (IC95% 13-266) IB 71 m (IC95% 45-96) IIA 35 m (IC95% 19-51) IIB 62 m (IC95% 34-90) IIIA 56 m (IC95% 0-141) 4. OS stage I vs II - by 7th edition: 93 vs 66 m, log Rank test, p = 0.016 - by 8th edition: 97 vs 70 m, log Rank test, p = 0.026 5. COPD as an adverse prognostic factor: meOS = 111 vs 55 months, log Rank test, p = 0.002
Conclusions
In our cohort of patients, the 8th edition of AJCC classification identifies better than the previous edition a group of patients with worse prognosis regarding to a higher size of the tumour and shiftening their pathological stage. Due to the small sample, we couldn’t prove a more accurate prognostic information for the new stage I categories in the 8th edition. COPD is confirmed in our serie as an adverse prognostic clinical factor.
Clinical trial identification
Legal entity responsible for the study
IDIS.
Funding
IDIS.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract